HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MTD
Mettler-Toledo International Inc.
MTD's fundamentals are strong: it turned 21% of its revenue into free cash flow and revenue grew 6.5%. At 38x earnings, it's trading in line with its usual 36x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MTD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
MTD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MTD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 31x | $1,406 | -19% |
| Forward | 34x | $1,731 | — |
| Fair | 36x | $1,655 | -4.4% |
| Current | 38x | $1,731 | — |
| Expensive | 46x | $2,122 | +23% |
Historical ranges are pointers, not guarantees.
MTD's PE is in its fair range at 38x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MTD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
MTD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MTD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $51.52 | +12% |
| Q3 2026 | $46.08 | +15% |
| Q2 2026 | $44.36 | +12% |
| Q1 2026 | $42.57 | +6.3% |
| Q4 2025 | $42.05 | +3.9% |
| Q3 2025 | $40.05 | +8% |
| Q2 2025 | $39.44 | +8.5% |
| Q1 2025 | $40.05 | +12% |
| Q4 2024 | $40.48 | +13% |
MTD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MTD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MTD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +6.3% |
| Q2 2026 | $1B | +4.5% |
| Q1 2026 | $947.1M | +7.2% |
| Q4 2025 | $1.1B | +8.1% |
| Q3 2025 | $1B | +7.9% |
| Q2 2025 | $983.2M | +3.9% |
| Q1 2025 | $883.7M | -4.6% |
| Q4 2024 | $1B | +12% |
MTD's revenue has grown year over year for six quarters in a row: $1.1B last quarter, up 6.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 27% | +1.3 points |
| Q2 2026 | 28% | +2.9 points |
| Q1 2026 | 22% | -0.7 points |
| Q4 2025 | 29% | -1 points |
| Q3 2025 | 26% | -1 points |
| Q2 2025 | 25% | -0.4 points |
| Q1 2025 | 23% | -1 points |
| Q4 2024 | 30% | +5.2 points |
MTD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MTD on cash flow, with more consistent year-over-year improvement.
MTD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $281.5M | +2.4% |
| Q2 2026 | $282.6M | +33% |
| Q1 2026 | $122.4M | -31% |
| Q4 2025 | $184.1M | -18% |
| Q3 2025 | $274.9M | +18% |
| Q2 2025 | $212.5M | -9.1% |
| Q1 2025 | $177.2M | +2.7% |
| Q4 2024 | $224.9M | -9.7% |
MTD's free cash flow has been positive every quarter for six years: $871M over the past year, down 2.1% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MTD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MTD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -148K shares |
| 1 year | -2.7% | -552K shares |
| 3 years | -8.5% | -1.9M shares |
| 5 years | -14% | -3.4M shares |
| Available history | -19% | -4.6M shares |
MTD has 20M diluted shares, down 2.7% from a year ago, with $782M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $226.2M |
| Q2 2026 | $206.3M |
| Q1 2026 | $206.3M |
| Q4 2025 | $143.7M |
| Q3 2025 | $218.7M |
| Q2 2025 | $218.7M |
| Q1 2025 | $218.7M |
| Q4 2024 | $212.5M |
MTD spent $782M buying back its own shares over the past year, down 9.9% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MTD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.7x | Healthy |
| Q4 2024 | 1.8x | Healthy |
MTD's net debt is about 1.6 years of its operating earnings (EBITDA), down from 1.9 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MTD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.7 | Overbought |
| Stochastic | 86.2 | Overbought |
MTD's weekly RSI is 74 (overbought) and its Stochastic is 86 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MTD PE vs Healthcare Sector
| Metric | MTD | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 26x | 45% above |
| PE % | 58 | 29 | 29 pts above |
MTD is trading at 38x earnings, a 45% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MTD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,621.0 | 6.8% above |
| 20 week MA | $1,465.0 | 18% above |
| 50 week MA | $1,359.5 | 27% above |
| 100 week MA | $1,302.9 | 33% above |
| 200 week MA | $1,308.6 | 32% above |
MTD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MTD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $792.8 | $1,140.2 | +44% |
| 2021 | $1,140.2 | $1,626.2 | +43% |
| 2022 | $1,626.2 | $1,439.1 | -12% |
| 2023 | $1,439.1 | $1,213.0 | -16% |
| 2024 | $1,213.0 | $1,234.2 | +1.8% |
| 2025 | $1,234.2 | $1,420.1 | +15% |
| 2026 YTD | $1,420.1 | $1,730.9 | +22% |
MTD has the edge over HIMS on returns for 2026, with the stronger performance.